Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment
Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients.
Bemdaneprocel therapy is at an early stage, and the year-long trial involved just 12 patients, but the positive outcome is viewed as significant after decades of setbacks in the hunt for an effective treatment. Developed by BlueRock therapeutics, a subsidiary of the pharmaceutical company Bayer, it was shown to be safe and the data gave a tantalising suggestion that patients may have benefited.
About Author
More Stories
Revealed: Chinese researchers can access half a million UK GP records
About 15% of world’s cropland polluted with toxic metals, say researchers
Rebecca Hendin on life outside our solar system – cartoon